Lecanemab - Revision history

MDElliottMD: Tier 1 taxonomy consolidation: removed redundant Category:Anti-dementia (canonical already present); removed redundant Category:Anti-Amyloid Antibodies (canonical already present)

2026-05-21T17:01:55Z

Tier 1 taxonomy consolidation: removed redundant Category:Anti-dementia (canonical already present); removed redundant Category:Anti-Amyloid Antibodies (canonical already present)

← Older revision		Revision as of 17:01, 21 May 2026
Line 25:		Line 25:

	[[Category:Anti-Dementia Medicines]]		[[Category:Anti-Dementia Medicines]]
	~~[[Category:Anti-dementia]]~~
	[[Category:Anti-Amyloid Monoclonal Antibodies]]		[[Category:Anti-Amyloid Monoclonal Antibodies]]
	~~[[Category:Anti-Amyloid Antibodies]]~~
	[[Category:Alzheimer Disease Medicines]]		[[Category:Alzheimer Disease Medicines]]

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:08Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 8:		Line 8:
	\| fda_max = 10 mg/kg q2w		\| fda_max = 10 mg/kg q2w
	\| routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting		\| routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting
	\| onset = Slowing of cognitive decline over 18 months (modest effect — ~27% relative slowing)		\| onset = Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing)
	\| duration = Ongoing dosing		\| duration = Ongoing dosing
	\| halflife = ~5-7 days		\| halflife = ~5-7 days
Line 16:		Line 16:
	\| intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB.		\| intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB.

	The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes — boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants.		The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes, boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants.

	The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree.		The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree.
	\| pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement.		\| pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement.
	\| effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages) — both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating.		\| effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages), both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating.
	\| interactions = <pharmaInteractions/>		\| interactions = <pharmaInteractions/>
	}}		}}

Maintenance script: Expand Lecanemab with Stahl-sourced detail (with skepticism)

2026-05-16T02:03:47Z

Expand Lecanemab with Stahl-sourced detail (with skepticism)

← Older revision		Revision as of 02:03, 16 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	~~\| generic = Lecanemab~~		\| brand = Leqembi
	\| brand = Leqembi		\| classes = Anti-amyloid beta (Aβ) monoclonal antibody, targets protofibrils
	~~\| structure =~~		\| mechanism = Humanized IgG1 monoclonal antibody with higher affinity for '''soluble Aβ protofibrils''' than for monomeric Aβ or insoluble plaques. The protofibril-targeting rationale: soluble oligomers and protofibrils are hypothesized to be the most neurotoxic Aβ species. Promotes microglial clearance and reduces protofibril burden.
	\| classes = Anti-~~dementia~~, ~~Monoclonal antibody~~		\| uses = Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023
	\| mechanism = ~~Anti~~-~~amyloid-beta~~ protofibril ~~antibody~~		\| starting_dose = 10 mg/kg IV every 2 weeks
	\| uses =		\| preparations = 200 mg/2 mL, 500 mg/5 mL vials for IV infusion
	\| starting_dose =		\| fda_max = 10 mg/kg q2w
	\| preparations =		\| routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting
	\| fda_max =		\| onset = Slowing of cognitive decline over 18 months (modest effect — ~27% relative slowing)
	\| routes =		\| duration = Ongoing dosing
	\| onset =		\| halflife = ~5-7 days
	\| duration =		\| bioavailability = 100% (IV)
	\| halflife =		\| pregnancy = Limited data
	\| bioavailability =		\| legal = Rx; REMS-like program for ARIA monitoring
	\| pregnancy =		\| intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB.
	\| legal =
	\| intro =		The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes — boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants.
	~~\| pharmacokinetics =~~
	~~\| pharmacodynamics =~~		The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree.
	~~\| indications =~~		\| pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement.
	\| ~~dosing~~ =		\| effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages) — both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating.
	\| effects =		\| interactions = <pharmaInteractions/>
	\| interactions = <pharmaInteractions/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}


	[[Category:Anti-Dementia Medicines]]		[[Category:Anti-Dementia Medicines]]
	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]
	[[Category:Anti-Amyloid Monoclonal Antibodies]]		[[Category:Anti-Amyloid Monoclonal Antibodies]]
			[[Category:Anti-Amyloid Antibodies]]
			[[Category:Alzheimer Disease Medicines]]

MDElliottMD: Comprehensive categorization: +Anti-Amyloid Monoclonal Antibodies

2026-05-15T18:42:22Z

Comprehensive categorization: +Anti-Amyloid Monoclonal Antibodies

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Anti-Dementia Medicines]]		[[Category:Anti-Dementia Medicines]]
	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]
			[[Category:Anti-Amyloid Monoclonal Antibodies]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:06Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Anti-Dementia Medicines]]
	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:56Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:38Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:54Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Lecanemab
+| generic            = Lecanemab
-| brand             = Leqembi
+| brand              = Leqembi
-| classes           = Anti-dementia, Monoclonal antibody
+| structure          =
-| mechanism         = Anti-amyloid-beta protofibril antibody
+| classes            = Anti-dementia, Monoclonal antibody
 }}
 [[Category:Anti-dementia]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Lecanemab
| brand = Leqembi
| classes = Anti-dementia, Monoclonal antibody
| mechanism = Anti-amyloid-beta protofibril antibody
}}
[[Category:Anti-dementia]]